Unknown

Dataset Information

0

A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension.


ABSTRACT: BACKGROUND:Azilsartan medoxomil (AZL-M), an angiotensin II receptor blocker, has been developed in fixed-dose combinations (FDCs) with chlorthalidone (CTD). OBJECTIVE/METHODS:We compared FDCs of AZL-M/CTD 20/12.5?mg once daily titrated to 40/25?mg if needed or AZL-M/CTD 40/12.5?mg once daily titrated to 80/25?mg if needed with an olmesartan medoxomil (OLM)-hydrochlorothiazide (HCTZ) 20/12.5?mg FDC once daily titrated to 40/25?mg if needed in a randomized, double-blind, 8-week study of 1085 participants with clinic SBP 160-190?mmHg and DBP 119?mmHg or less. Titration to higher doses occurred at week 4 if BP was at least 140/90?mmHg (?130/80?mmHg if diabetes or chronic kidney disease). The primary endpoint was change from baseline in clinic SBP; 24-h ambulatory BP monitoring was also measured. RESULTS:Greater reductions in clinic SBP from a baseline of 165?mmHg were observed (P?

SUBMITTER: Cushman WC 

PROVIDER: S-EPMC5862000 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension.

Cushman William C WC   Bakris George L GL   White William B WB   Weber Michael A MA   Sica Domenic D   Roberts Andrew A   Lloyd Eric E   Kupfer Stuart S  

Journal of hypertension 20180401 4


<h4>Background</h4>Azilsartan medoxomil (AZL-M), an angiotensin II receptor blocker, has been developed in fixed-dose combinations (FDCs) with chlorthalidone (CTD).<h4>Objective/methods</h4>We compared FDCs of AZL-M/CTD 20/12.5 mg once daily titrated to 40/25 mg if needed or AZL-M/CTD 40/12.5 mg once daily titrated to 80/25 mg if needed with an olmesartan medoxomil (OLM)-hydrochlorothiazide (HCTZ) 20/12.5 mg FDC once daily titrated to 40/25 mg if needed in a randomized, double-blind, 8-week stud  ...[more]

Similar Datasets

| S-EPMC8031288 | biostudies-literature
| S-EPMC8031057 | biostudies-literature
| S-EPMC8108858 | biostudies-literature
| S-EPMC6122257 | biostudies-literature
| S-EPMC8030929 | biostudies-literature
| S-EPMC8673073 | biostudies-literature
| S-EPMC4819539 | biostudies-literature
| S-EPMC3383350 | biostudies-other
| S-EPMC5024056 | biostudies-literature
| S-EPMC3546644 | biostudies-literature